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Introduction
G protein-coupled receptors (GPCRs) represent the largest
family of membrane proteins. About half of the clinically used
drugs today recognize GPCRs. It is now widely accepted that
different GPCRs can interact with each other and form com-
plexes, so-called heteromers. The first hypothesis on GPCR het-
eromers was raised in the early 1980s after observations of
neuropeptide-monoamine receptor–receptor interactions.[1, 2]
The existence of heteromers was confirmed almost twenty
years later for two nonfunctional GPCR monomers, g-amino
butyric acid (GABA) receptors, GABAB1 and GABAB2, which as-
semble at the cell surface in a signaling heterodimer, the
GABAB receptor.[3] Dimerization has now been described for
many GPCRs in in vitro settings, although evidence in native
tissue is still sparse.[4, 5]
In classical pharmacology, allosteric mechanisms were only
discussed in terms of intramolecular interactions within a re-
ceptor between orthosteric and allosteric sites. Nowadays,
there is mounting evidence that intermolecular receptor–re-
ceptor interactions may also result in altered receptor recogni-
tion, pharmacology and signaling. Heterobivalent ligands have
been proven useful as molecular probes for confirming and
targeting heteromeric receptors,[6–8] such as k- and d-opioid re-
ceptor heteromers.[7]
There are five dopamine receptor subtypes that can be di-
vided into two distinct subfamilies : D1-like (D1R and D5R) and
D2-like (D2R, D3R, and D4R). In this study we focus on the heter-
odimerization of the dopamine D2-like receptors (D2-likeR) and
the m-opioid receptor (mOR). D2-likeR and mOR are GPCRs, ex-
pressed in the brain, which play a major role in schizophrenia,
Parkinson’s disease, addiction, and pain. Heterobivalent ligands
are valuable tools to demonstrate the presence of receptor
heteromers even in native tissue and can be used to study a
specific GPCR dimer behavior without any receptor modifica-
tion.[9–11] Such compounds may also eventually evolve to useful
pharmacological agents.[10] Heterobivalent ligands with a
spacer of optimal length are envisaged to exhibit potency
greater than that derived from the two monovalent pharmaco-
phores and may allow the targeting of certain heteromeric
subtypes, increasing the selectivity of drug action.[11–13]
The dopaminergic and opioid peptide system are pharmaco-
logical targets for the treatment of addiction and chronic pain.
They show an impressive co-distribution in many nuclei of the
brain, which enables intermolecular receptor–receptor interac-
tions[14,15] that may be relevant for the treatment of addiction
and chronic pain. In vivo studies indicate the presence of
cross-regulation between the D2-likeR and the mOR. Activation
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of dopaminergic receptors causes a transient decrease in mOR
immunoreactivity. Additionally, D2-likeR/mOR interactions mod-
ulate morphine-induced upregulation of certain transcription
factors such as c-Fos, dFosB, and P-CREB.[16–19] These results can
be explained by the presence of direct D2-likeR–mOR interac-
tions. Furthermore, we have identified heterodimerization of
D2R–mOR and D4R–mOR by co-immunoprecipitation (co-IP) and
bioluminescence resonance energy transfer (BRET) studies in
mammalian transfected cells (unpublished results). Therefore,
all results discussed above indicate that D2-likeR (especially D2R
and D4R) and mOR heterodimers could be therapeutic targets
for the treatment of addiction and chronic pain.
Herein we report the design and synthesis of a series of het-
erobivalent mOR agonist/antagonist–D2-likeR agonist/antago-
nist ligands as pharmacological tools to further study mOR–D2-
likeR (mOR–D2R and mOR–D4R) heteromers. In these com-
pounds, the D2-likeR agonist/antagonist and the mOR agonist/
antagonist were linked through a spacer of variable length.
The spacers were based on polyethylene glycol (PEG) unit re-
peats, and their size was varied (from 18 to 24 atoms) to probe
the best interaction with mOR–D2-likeR heteromers. The bind-
ing properties of these compounds were determined by radio-
ligand binding studies in membrane preparations and intact
cells. Furthermore, mitogen-activated protein kinase (MAPK)
phosphorylation and b-arrestin 2 recruitment assays were per-
formed to test the pharmacological response of the ligands for
D2-likeR and mOR, respectively. Experiments to evaluate the
binding of the heterobivalent ligands to mOR and D2-likeR
were performed in cells expressing both mOR and D2-likeR.
Design of heterobivalent ligands based on the structure of
D2-likeR ligands and mOR ligands
As depicted in Figure 1, the bivalent ligands were derived from
the mOR-specific agonist hydromorphone (HM) and the struc-
turally related mOR antagonist naltrexone (NTX). As D2-likeR li-
gands we used the antagonist 1,4-disubstituted aromatic pi-
perazines (DAPs, 3)[20] and the agonist 5-hydroxy-2-(dipropyla-
mino)tetralin (DPAT, 7)[11] that were equipped with an appropri-
ate ligation handle.
The dimeric ligands were constructed around PEG spacers of
variable length that were equipped with a carboxylic acid on
one and an azide on the other end (Figure 2). The use of PEG
linkers precludes cumulative incremental increases in hydro-
phobicity that would occur upon homologation if an alkyl
chain were used. With the use of existing procedures both
opioid ligands 1a and 1b were converted into their corre-
sponding 6’-R-amino derivatives 2a and 2b. The introduced
Figure 1. Designed heterobivalent ligands.
Figure 2. Overview of used monovalent ligands and spacer molecules with appropriate ligation handles.
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amine groups allow coupling to the PEG spacers via an amide
bond, whereas the azido group on the PEG linker allows facile
connection to the alkyne derived dopamine ligands via a
copper-catalyzed azide–alkyne cycloaddition (CuAAC) reaction.
The choice of the position and nature of the attachment
points for linking the two pharmacophore units to the spacer
relies on two criteria: the feasibility of the chemical modifica-
tion and the compatibility of the modification with the biologi-
cal activity (SAR data) of the pharmacophore.
As indicated above, the selected D2-likeR ligands need to be
functionalized with an alkyne moiety to allow conjugation to
the azide group of the PEG linkers. The intrinsic activity of
DAPs for D2-likeR is determined by an aromatic headgroup and
an amine moiety, which forms a strong hydrogen bond to the
crucial Asp3.32 residue in the transmembrane helix 3 (TM3) of
D2R.
[20] A lipophilic appendage is necessary for enhancing
ligand affinity. Because proper elongation of this appendage is
expected to lead to the “entrance region” of the receptor and
from there to the binding pocket of a neighboring protomer,
the para position of an aromatic moiety terminating this ap-
pendage is considered an appropriate point of attachment for
a linker unit.[20] Vanillin allows facile introduction of an alkyne
group in the para position, while reductive amination permits
coupling to the phenylpiperazine moiety.
DPAT is a prototypical D2R/D3R agonist suitable for construct-
ing bivalent ligands.[21] Site-directed mutagenesis has demon-
strated that the 2-aminotetralin moiety interacts with an ago-
nist binding domain involving TM3 and TM5 for activation of
either D2R or D3R. The basic nitrogen atom and the 5-hydroxy
group are critically important for binding affinity. A known ani-
line derivative of DPAT[11] was coupled with 4-pentynoic acid to
afford compound 7 with an alkyne group for CuAAC reaction.
Results and Discussion
Chemistry
Individual components of the bivalent ligands
As mOR ligands the known R-amines 2a and 2b were prepared
from NTX (1a) and HM (1b), respectively, according to pub-
lished procedures.[22] Briefly, compounds 1a and 1b were con-
verted into the corresponding oximes, which were reduced to
6R-amines 2a and 2b in the presence of ZrCl4 and NaBH4. Al-
though previous studies showed little stereoselectivity in
opioid binding for 6R versus 6S amine diastereomers,[23] the
predominant R diastereomers were separated from their S epi-
mers by silica gel chromatography, to facilitate further charac-
terization.
For the synthesis of the first alkyne-functionalized D2-likeR
ligand, DPAT (7), commercially available 5-methoxyl-2-tetralone
(4) was converted into the 1,2,3,4-tetrahydronaphthalen-2-
amine derivative 5 in four steps following published proce-
dures.[11] Arylamine 5 was coupled with 4-pentynoic acid to
give amide 6. Deprotection of the methyl ether with Me2SBF3
in CH2Cl2 gave the desired compound 7 (Scheme 1). The
alkyne-functionalized D2-likeR ligand DAP (3) was synthesized
by starting from vanillin as described earlier by Kehhorn
et al.[20] The bifunctional PEG linkers were prepared as de-
scribed earlier.[24–26]
Bivalent ligand synthesis
The bivalent ligands were generated by first condensing each
of the two mOR ligands with each of the three PEG linkers in
the presence of the coupling agent EDC and triethylamine to
yield the six intermediate azides 11a–f (Scheme 2). The series
Scheme 1. Reagents and conditions: a) 4-pentynoic acid, (3-dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride, triethylamine, CH2Cl2, RT, overnight;
b) Me2SBF3, CH2Cl2, RT, overnight.
Scheme 2. Reagents and conditions: a) (3-dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride, 1-hydroxybenzotriazole, triethylamine, CH2Cl2.
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of bivalent ligands was finalized by conjugating each of the six
azides to both DPAT and DAP through CuAAC (Scheme 3). This
yielded a concise series of 12 bivalent D2-likeR–mOR ligands in
which each of the sets of ligands and the three linkers are sys-
tematically represented.
Ligand binding assays
Evaluating the binding of bivalent ligands to the D2-likeR
A saturation binding assay for [3H]spiperone, a nonselective an-
tagonist of D2-likeR, was described previously.
[27,28] Here we
performed a competition assay to evaluate the binding of the
bivalent ligands to the D2-likeR D2R and D4R. First the binding
affinity of the bivalent ligands 12a–f and 13a–f along with
their alkynylated DAP and DPAT precursors 3 and 7 was mea-
sured by displacement of [3H]spiperone from the D4R ex-
pressed in HEK293T cells, indicating that all the bivalent ligands
bind to the D4R (Table 1). However, a clear decrease in the D4R
binding affinities of the bivalent ligands was detected relative
to the alkynes 3 and 7. Compound 12d with a short spacer
Scheme 3. Reagents and conditions: a) sodium ascorbate, CuSO4, triethylamine, tris[(1-benzyl-1,2,3-triazol-4-yl)methyl]amine, dimethylformamide.
Table 1. Binding affinities for D4R and D4R–mOR.
Compd R1 R2 n Ki [nm]
[a]
D4R D4R–mOR
3 – – – 1.6:0.2 2.1:0.3
12a OH CH2cPr 3 117:12 nd[b]
12b OH CH2cPr 4 214:11 219:10
12c OH CH2cPr 5 226:18 nd
12d H CH3 3 184:35 –
12e H CH3 4 369:42 368:10
12 f H CH3 5 339:50 417:8.8
7 – – – 15:6.1 16:2.5
13a OH CH2cPr 3 118:12 101:1.3
13b OH CH2cPr 4 157:30 nd
13c OH CH2cPr 5 138:25 nd
13d H CH3 3 110:9.3 nd
13e H CH3 4 191:9.5 394:12
13 f H CH3 5 199:16 493:11
[a] Binding affinities were obtained by competitive displacement of radio-
labeled [3H]spiperone binding to HEK293T D4R and HEK293T D4R–mOR
membranes. All values are the mean:SEM of three independent assays
using 11 different ligand concentrations, each performed in duplicate.
[b] Not determined.
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length (18 atoms) showed a slightly higher affinity for D4R
than 12e and 12 f. This trend was also apparent for the other
bivalent ligands (12a, 13a and 13d) possessing the same
spacer as 12d. In a next step we wanted to compare the affini-
ty of the bivalent ligands for D4R in the absence and presence
of overexpressed mOR. Unexpectedly, no major differences in Ki
values were found between both experimental setups, except
for 12d. Interestingly, a biphasic competition curve was ob-
served for 12d from which two individual affinity constants
could be derived (Ki high 1.2:0.3 nm and Ki low 207:51 nm, Fig-
ure 3a). Such biphasic competition binding curves are indica-
tive of a bivalent binding mode.[11] Specifically, the high-affinity
Ki value represents a bivalent receptor-bridging binding mode
of 12d to D4R/mOR heterodimer, whereas the low-affinity Ki
value reveals a monovalent binding mode to D4R. Bivalent
ligand 12d thus displays a 170-fold preference for the high-af-
finity bivalent interaction with the D4R/mOR heterodimer over
monovalent binding mode to D4R.
By following the same approach and still using
[3H]spiperone as the radioligand, we also tested the affinity of
the bivalent ligand 12d and its corresponding monovalent
ligand 3 to the D2R and D2R–mOR receptors. The affinities of
compound 12d to D2R and D2R–mOR decreased three-fold rela-
tive to the ligand 3 for both receptors (Table 2). Unfortunately,
we only obtained a monophasic competition binding curve for
12d to D2R–mOR, and no major differences in binding affinity
were observed between cells expressing only D2R and cells ex-
pressing both D2R and mOR (Figure 3b).
Next, following a similar protocol, we determined the affinity
of monomeric ligand 3 and bivalent ligand 12d on cells ex-
pressing D2R and D2R–mOR, using an alternative radioligand,
[3H]raclopride. Raclopride, which acts as a selective D2R antago-
nist, is more hydrophilic and has substantially less nonspecific
binding in intact cells than spiperone. Furthermore, it is not
cell permeable, rendering the assay possibly more sensitive, as
binding of the radioligand to be displaced is restricted to re-
ceptors in the plasma membrane. In this experiment (Table 3)
the affinities of 12d to D2R and D2R–mOR were 32.4:8.5 nm
and 38.6:3.2 nm, respectively, while the affinities of the mon-
ovalent alkyne 3 were 43.1:9.0 nm and 49.9:5.8 nm, respec-
tively. Still, only one-site binding curves for 12d were obtained
from cells mono-expressing D2R and cells co-expressing D2R
and mOR (Supporting Information). The saturation binding data
for [3H]raclopride can be found in the Supporting Information.
Interestingly, we found that the affinity of 12d for D4R de-
creased 100-fold relative to the monovalent ligand 3, while its
Ki value for D2R only decreased three-fold.
Evaluating the binding of the bivalent ligands to mOR
We performed competitive receptor binding assays in cell
membranes expressing mOR to determine the binding affinity
of bivalent ligands, using the tracer [3H]diprenorphine, which is
a nonselective opioid antagonist. Saturation binding assays
showed that the Kd value and Bmax of [
3H]diprenorphine were
0.21:0.064 nm and 489:28 fmolmg@1 for mOR, respectively.
In the competition assay the binding affinities for the monova-
Figure 3. Representative competition curves for bivalent ligand 12d. D2-
likeR binding of the bivalent ligand 12d was measured by displacement of
the radiolabeled [3H]spiperone from membranes of HEK293T cells co-ex-
pressing D4R/mOR (or D2R/mOR) or mono-expressing D4R (or D2R) only. a) D4R
binding of 12d in the presence (&, Ki high 1.2:0.3 nm, Ki low 207:51 nm) or
absence (&, Ki 184:35 nm) of mOR. b) D2R binding of 12d in the presence
(*, Ki 101:10 nm) or absence (*, Ki 62:3 nm) of mOR. Data are the
mean:SEM of three independent assays, each performed in duplicate.
Table 2. Binding affinities for D2R and D2R–mOR.
Compd Ki [nm]
[a]
D2R D2R–mOR
3 22:5 32:11
12d 62:3 101:10
[a] Binding affinities were obtained by competitive displacement of radio-
labeled [3H]spiperone binding to HEK293T D2R and HEK293T D2R–mOR
membranes. All values are the mean:SEM of at least two independent
assays.
Table 3. Binding affinities (Ki) for D2R and D2R–mOR.
Compd Ki [nm]
[a]
D2R D2R–mOR
3 43.1:9.0 49.9:5.8
12d 32.4:8.5 38.6:3.2
[a] Binding affinities were obtained by competitive displacement of radio-
labeled [3H]raclopride binding to HEK293T D2R and HEK293T D2R–mOR
intact cells. All values are the mean:SEM of at least two independent ex-
periments.
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lent ligands HM and NTX were 4.4:0.21 nm and 7.8:0.16 nm,
respectively (Table 4). Compounds 12a–c and 13a–c, which
were derived from NTX, exhibited a binding affinity for mOR
similar to that of NTX, whereas bivalent ligands 12b and 13b,
with a 21-atom spacer, displayed relatively lower Ki values than
the other NTX-based ligands. HM-based bivalent ligands 12d–f
and 13d–f showed a small decrease in the binding affinities
for mOR relative to the corresponding monovalent compound
HM, except for 12e (3.7:0.02 nm) and 13e (7.2:0.53 nm)
with a medium spacer length (21 atoms). Therefore, the affini-
ties of bivalent ligands with a medium-length spacer (21
atoms) to mOR were relatively higher than the other ligands
with shorter (18 atoms) or longer linkers (24 atoms).
Functional assays
MAPK phosphorylation to study D2-likeR activation by the
newly developed bivalent ligands
The mitogen-activated protein kinase (MAPK) phosphorylation
assay was used to define the functional activity of the bivalent
ligands. The MAPK pathway, also known as the extracellular-
signal-regulated kinase (ERK) pathway, consists of an intracellu-
lar chain of proteins that transfer the signal from the cell sur-
face receptor to the nuclear DNA or other subcellular targets
causing cellular responses. Signaling molecules in this pathway
communicate with each other by adding a phosphate group
to the neighboring protein. This phosphorylation event func-
tions as an on/off switch, leading to the activation or inhibition
of the next signaling molecule in the chain.[29] The most com-
monly studied element of the MAPK pathway, initiated by
GPCR activation, is the phosphorylation of p44/42 MAPK
(ERK1/2).
To assess functional activation of the D2R and D4R by the
above described bivalent ligands, we used a HEK293 cell line
stably expressing the D2R and D4R, respectively.
[30] Unexpected-
ly, the signal band of MAPK-P for D2R was quite weak (see Sup-
porting Information). Nevertheless, we found a strong immu-
noreactive band (Figure 4) for MAPK-P upon activation of D4R
with the agonist dopamine (DA), and with the alkynylated DAP
(3) and DPAT (7). Next, all bivalent ligands were tested in this
cell system (Figure 5 and Table 5). We can conclude that all bi-
valent ligands activate the MAPK signaling pathway. Interest-
ingly, compound 12d with an 18-atom linker (shown in
Table 5) displayed modestly high potency (EC50=0.12:
0.04 mm) and relatively high efficacy (92:1%) as compared
with the monovalent ligand 3 (EC50=0.21:0.12 mm, Emax=
75:2%), while the potency of compounds 12a–c decreased
8- to 16-fold relative to 3. In addition, all the DAP-bond li-
gands, except for 12d, showed similar efficacy (Emax=72–85%)
Table 4. Binding affinities for mOR.
Compd R1 R2 n Ki [nm]
[a]
HM H CH3 – 4.4:0.21
NTX OH CH2cPr – 7.8:0.16
12a OH CH2cPr 3 6.3:1.1
12b OH CH2cPr 4 4.6:0.25
12c OH CH2cPr 5 9.2:0.41
13a OH CH2cPr 3 7.5:0.95
13b OH CH2cPr 4 3.8:0.84
13c OH CH2cPr 5 7.6:0.39
12d H CH3 3 16:0.87
12e H CH3 4 3.7:0.02
12 f H CH3 5 11:0.57
13d H CH3 3 13:1.2
13e H CH3 4 7.2:0.53
13 f H CH3 5 17:3.4
[a] Binding affinities were obtained by competitive displacement of radio-
labeled [3H]diprenorphine binding to HEK293T mOR. All values are the
mean:SEM of three independent assays.
Figure 4. Stimulation of MAPK phosphorylation upon D4R agonist treatment,
as determined by immunoblotting assays. Cells were treated with serum-
free media (SFM) for 12 h. Next, D2-likeR agonists (10 mm), SFM or vehicle
control were added for 5 min. Cells were washed and lysed as explained in
the Experimental Section. Phosphorylated MAPK was detected by immuno-
blotting using rabbit anti-phospho-p44/42 MAPK antibody, and mouse anti-
p44/42 MAPK antibody was used for demonstrating equal protein loading.
The results are representative of three independent experiments; DA=dop-
amine.
Figure 5. Efficacy of bivalent ligands to phosphorylate MAPK in HEK293 D4R
cells. Cells were treated with serum-free media (SFM) for 12 h. Next, D2-likeR
agonists (10 mm) and SFM were added for 5 min. Cells were washed and
lysed as explained in the Experimental Section. Phosphorylated MAPK was
detected by immunoblotting using rabbit anti-phospho-p44/42 MAPK anti-
body, and mouse anti-p44/42 MAPK antibody was used for demonstrating
equal protein loading. The top panel shows a representative result from
three independent experiments; the bottom panel is given as mean:SEM;
DA=dopamine.
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as compound 3. On the other hand, DPAT-based bivalent li-
gands had potency (EC50=0.45–0.95 mm) and efficacy (Emax=
86–108%) similar to those of 7 (EC50=0.37:0.17 mm, Emax=
100:3%). Overall, bivalent ligand 12d with a short linker
length (18 atoms) was the most potent compound to activate
the MAPK phosphorylation of D4R.
b-Arrestin 2 recruitment to mOR
To assess activation of the mOR, the HEK293 cell line was used
to stably express the mOR. Unfortunately, we did not obtain
any good results from MAPK-P for mOR (data not shown). We
then performed a b-arrestin 2 recruitment assay based on the
NanoLuc Binary Technology (NanoBiT).[31] Our research group
recently reported the application of this assay for monitoring
GPCR activation, via ligand-induced interaction of b-arrestin 2
with CB1 and CB2 cannabinoid receptors.[32] Here, we opti-
mized this assay for ligand induced interaction of b-arrestin 2
with mOR. Agonists of mOR, such as [d-Ala2,N-MePhe4,Gly-ol]-
enkephalin (DAMGO), have previously been shown to induce
robust receptor phosphorylation, b-arrestin 2 recruitment, and
mOR trafficking.[33,34] On the other hand, morphine is a poor in-
ducer of receptor phosphorylation, b-arrestin 2 recruitment,
and internalization of mOR. However, upon overexpression of
G protein-coupled receptor kinase (GRK2) in cell culture, mor-
phine gained the capacity to induce mOR phosphorylation, ac-
companied by the rescue of b-arrestin 2 recruitment.[34,35]
To assess the ligand-induced interaction of b-arrestin 2 with
mOR, overexpression of GRK2 in cell culture was performed.
Our results show that DAMGO induces robust b-arrestin 2 re-
cruitment even in the absence of GRK2. On the other hand,
HM could promote b-arrestin 2 recruitment only when GRK2
was overexpressed in HEK293 cells. Both results are in line with
those found in the literature (see Supporting Information
Figure 2).
Upon stimulation with a known agonist of mOR, HM, mOR-
SmBiT showed a concentration dependent interaction with
LgBiT-b-arrestin 2 in the presence of GRK2 (Figure 6). Also, for
the bivalent ligands containing the agonistic HM-based mono-
mer, concentration dependence was obtained, and EC50 values
were determined as a measure of relative potency (Table 6 and
Figure 6). Ranging from 12.73 nm to 57.06 nm, all the EC50
values of the bivalent ligands were similar to that of the
parent HM (EC50=30.09 nm). Amongst the DAP-based ligands,
compound 12d, having the shortest linker (18 atoms), showed
excellent potency (EC50=12.73 nm) and high efficacy (85:
3%). Remarkably, all DPAT-based ligands showed lower effica-
cies than DAP-bond ligands, with compound 13d having the
same spacer as 12d, displaying the lowest efficacy (24:1%)
amongst the DPAT-based ligands.
Conclusions
In summary, we have designed and synthesized a series of
novel heterobivalent ligands based on the chemical structure
of two distinct D2-likeR ligands and a mOR agonist and antago-
nist. Ligation of mOR ligands does not perturb the affinity for
mOR. mOR bivalent ligands derived from the HM agonist are
still capable of activating the mOR signaling pathway as dem-
onstrated by b-arrestin 2 recruitment. Furthermore, bivalent
ligand 12d containing the shortest linker (18 atoms) showed
excellent potency and high efficacy both in b-arrestin 2 recruit-
ment for mOR and MAPK-P for D4R. On the other hand, ligation
of D2-likeR ligands negatively influences the affinity for D2R
Table 5. Potency of D2-likeR agonists induced MAPK-P in HEK293 D4R
cells.
Compd R1 R2 n EC50 [mm]
[a] Emax [%]
[b]
DA – – – 0.037:0.012 100:4
3 – – – 0.21:0.12 75:2
12a OH CH2cPr 3 3.4:0.2 78:3
12b OH CH2cPr 4 1.9:0.3 77:2
12c OH CH2cPr 5 1.6:0.1 72:1
12d H CH3 3 0.12:0.04 92:1
12e H CH3 4 0.31:0.02 85:5
12 f H CH3 5 0.80:0.06 76:2
7 – – – 0.37:0.17 100:3
13a OH CH2cPr 3 0.55:0.24 89:4
13b OH CH2cPr 4 0.48:0.06 86:4
13c OH CH2cPr 5 0.88:0.01 90:1
13d H CH3 3 0.95:0.03 97:1
13e H CH3 4 0.57:0.14 101:6
13 f H CH3 5 0.45:0.01 108:2
[a] Data are the mean:SEM of three independent experiments. [b] Emax
relative to the effect of the reference agonist dopamine at 10 mm.
Figure 6. Concentration-dependent interaction of mOR with b-arrestin 2
upon stimulation with agonists of mOR. Data are the mean:SEM of at least
two independent experiments.
Table 6. Potency and maximal effect of mOR agonists on b-arrestin 2 re-
cruitment for mOR.
Compd R1 R2 n EC50 [nm] (95% CI)
[a] HM [%][b]
HM H CH3 – 30.09 (24.51–36.94) 100
12d H CH3 3 12.73 (7.612–21.28) 85:3
12e H CH3 4 40.38 (30.41–53.61) 68:1
12 f H CH3 5 34.86 (25.76–47.18) 64:1
13d H CH3 3 13.41 (8.286–23.15) 24:1
13e H CH3 4 57.06 (38.49–84.58) 28:1
13 f H CH3 5 14.09 (10.14–21.08) 38:1
[a] EC50 values are a measure of potency for b-arrestin 2 recruitment. Data
are given as EC50 values (95% CI profile likelihood). [b] Percent maximal
stimulation relative to the agonist HM at 10 mm.
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and D4R when using [
3H]spiperone as the radioligand. Howev-
er, a biphasic competition binding curve was observed for 12d
to D4R–mOR, which indicates a bivalent binding mode.
[11, 36]
Hence, compound 12d could bridge the D4R–mOR heterodi-
mer.
Unexpectedly, we were unable to identify bivalent ligands
that show a biphasic binding mode or a significant increase in
affinity for cells expressing both the D2R and the mOR, com-
pared with cells that only express D2R. This indicates that none
of the bivalent ligands are capable of binding both receptors
simultaneously, possibly owing to a suboptimal length or
nature of the selected linkers, which, however, were based on
the spacers of class A GPCR bivalent ligands.[20,37] On the other
hand, it cannot be excluded that subtle differences such as dif-
ferences in the dissociation rate of the ligands remain unde-
tected by comparing equilibrium dissociation constants. In a
study investigating adenosine A3 receptors, it was found that
ligand binding kinetics is found to be influenced in membrane
microdomains as a consequence of receptor dimerization.[38]
While future studies will try to address these shortcomings,
the current study already gives access to the monomeric li-
gands that are equipped with appropriate ligation handles to
construct second-generation bivalent ligands with alternative
spacers. In conclusion, the present results provide useful in-
sight into development of new bivalent ligands as tools to in-
vestigate the mOR-D4R heterodimer.
Experimental Section
Chemistry
All reactions described were performed under an N2 atmosphere
and at ambient temperature unless stated otherwise. All regents
and solvents were purchased from Sigma–Aldrich (Diegem, Bel-
gium), Fisher Scientific (Merelbeke, Belgium), TCI Europe (Zwijn-
drecht, Belgium) or Apollo Scientific (Bredbury, Stockport, UK) and
used as received. NMR solvents were acquired from Eurisotop
(Saint-Aubin, France). Reactions were monitored by TLC analysis
using TLC aluminum sheets (Macherey–Nagel, Alugram Sil G/
UV254) with detection by spraying with a solution of
(NH4)6Mo7O24·4H2O (25 gL
@1) and (NH4)4Ce(SO4)4·2H2O (10 gL
@1) in
H2SO4 (10% aq) followed by charring or an aqueous solution of
KMnO7 (20 gL
@1) and K2CO3 (10 gL
@1) or an ethanolic solution of
ninhydrin (2 gL@1) and acetic acid (1% v/v) followed by charring.
Solution pH values were estimated using universal indicator paper
(Merck). Silica gel column chromatography was performed using a
Grace Reveleris X2 system and the corresponding silica gel car-
tridges. ESI-HRMS spectra were measured with a Waters LCT Pre-
mier XE Mass spectrometer calibrated using leucine enkephalin as
an external standard. 1H- and 13C-APT-NMR spectra were recorded
with a Varian Mercury-300BB (300/75 MHz) spectrometer. Chemical
shifts are given in ppm (d) relative to tetramethylsilane as an inter-
nal standard (1H NMR) or the NMR solvent (13C NMR). Coupling con-
stants are given in Hertz (Hz). Weak signals in 13C NMR are indicat-
ed as (w). LC–MS analyses were carried out on a Waters AutoPurifi-
cation System equipped with PDA and ESI-MS detection and using
a Waters CORTECS C18 column (4.6V100 mm, 2.7 mm) and a water/
acetonitrile/formic acid linear gradient system at a flow rate of
1.44 mLmin@1.
General procedure 1: Carbodiimide-mediated amide
formation
To a solution of (3-dimethylaminopropyl)-N-ethylcarbodiimide hy-
drochloride (1.5 equiv) and 1-hydroxybenzotriazole (1.4 equiv) in
CH2Cl2 was added a solution of the PEG spacer (1.2 equiv) in CH2Cl2
(0.2m) and cooled to 0 8C under an argon atmosphere. After
15 min at 0 8C, amines 2a,b (1.0 equiv) were added and triethyla-
mine (2 equiv) was added dropwise; the reaction was slowly
warmed to room temperature and stirred overnight. The reaction
was diluted with CH2Cl2, washed successively with water, HCl (5%
aq), NaHCO3 (sat. aq), NaCl (sat. aq), dried over Na2SO4, filtered and
solvent was evaporated under reduced pressure. The crude prod-
uct was purified by silica gel chromatography (NH4OH/MeOH/
CH2Cl2, 1:5:94 v/v/v) to yield the amides 11a–f.
General procedure 2: Copper mediated azide-alkyne
cycloaddition
To a solution of the intermediate azide (1.0 equiv) in dimethylfor-
mamide (0.1m) was added the alkyne (1.5 equiv), sodium ascorbate
(1.0 equiv, 0.5m), CuSO4 (0.2 equiv, 0.05m), triethylamine (3.0 equiv)
and a catalytic amount of tris[(1-benzyl-1,2,3-triazol-4-yl)methyl]a-
mine. The reaction mixture was stirred overnight at room tempera-
ture in the dark under an argon atmosphere. The solvent was
evaporated under reduced pressure and the residue was redis-
solved in water and extracted with CH2Cl2. Then combined organic
fractions were pooled, washed with brine and dried over Na2SO4.
The crude compound was purified by silica gel chromatography
(NH4OH/MeOH/CH2Cl2, 1:5:94 v/v/v) to give the final compound as
a white solid (yield, 40–57%).
N-(4-(2-((5-methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)(propyl)-
amino)ethyl)phenyl)pent-4-ynamide (6): To a solution of (3-dime-
thylaminopropyl)-N-ethylcarbodiimide hydrochloride (1.1 g,
4.92 mmol) in CH2Cl2 (20 mL) was added a solution of 4-pentynoic
acid (0.39 g, 3.93 mmol) in CH2Cl2 (5 mL) followed by a solution of
5 (1.1 g, 3.28 mmol) in CH2Cl2 (5 mL). The mixture was cooled to
0 8C and triethylamine (0.68 mL, 4.92 mmol) was added dropwise;
the reaction was slowly warmed to room temperature and stirred
overnight. The reaction was diluted with CH2Cl2, washed succes-
sively with water, HCl (5% aq), NaHCO3 (sat. aq), NaCl (sat. aq),
dried over Na2SO4, filtered and solvent was evaporated under re-
duced pressure. The crude product was purified by silica gel chro-
matography (hexane/EtOAc, 3:2 v/v) to give 6 as a pale-yellow
solid (1.32 g, 95%). 1H NMR (300 MHz, CDCl3): d=7.42 (d, J=
8.4 Hz, 2H), 7.15 (d, J=8.4 Hz, 2H), 7.07 (t, J=7.9 Hz, 1H), 6.69 (d,
J=7.8 Hz, 1H), 6.62 (d, J=8.1, 1H), 3.78 (s, 3H), 3.04–2.91 (m, 2H),
2.91–2.80 (m, 1H), 2.79–2.63 (m, 6H), 2.63–2.53 (m, 7H), 2.05 (d,
J=3.2 Hz, 2H), 1.61–1.41 (m, 3H), 0.88 ppm (t, J=7.3 Hz, 3H);
13C NMR (75 MHz, CDCl3): d=169.4, 157.2, 137.9, 137.0, 135.7,
129.2, 126.1, 125.2, 121.6, 120.1, 106.9, 82.9, 69.5, 56.7, 55.2, 52.9,
52.6, 36.1, 35.4, 32.3, 25.7, 23.8, 22.2, 14.8, 11.9 ppm; HRMS (ESI) m/
z : calculated for C27H35N2O2 [M+H]
+ 419.2699, found 419.2705.
N-(4-(2-((5-hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)(propyl)-
amino)ethyl)phenyl)pent-4-ynamide (7): To a solution of 6
(1.05 g, 2.51 mmol) in CH2Cl2 (20 mL) was added boron trifluoride
methyl sulfide complex (4.77 mL, 45.21 mmol). The reaction was
stirred overnight under nitrogen at room temperature. The mixture
was treated with a saturated aqueous NaHCO3 solution, extracted
with CH2Cl2, dried over Na2SO4 and the solvent was evaporated
under reduced pressure. The crude product was purified by silica
gel chromatography (hexane/EtOAc, 1:1 v/v) to yield 7 as a white
foam (750 mg, 74%). 1H NMR (300 MHz, CDCl3): d=7.41 (d, J=
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8.4 Hz, 2H), 7.14 (d, J=8.4 Hz, 2H), 6.97 (t, J=7.8 Hz, 1H), 6.66 (d,
J=7.5 Hz, 1H), 6.59 (d, J=7.8 Hz, 1H), 3.02–2.94 (m, 2H), 2.90–2.82
(m, 1H), 2.79–2.66 (m, 6H), 2.62–2.53 (m, 7H), 2.05 (d, J=3.2 Hz,
2H), 1.66–1.56 (m, 1H), 1.53–1.46 (m, 2H), 0.89 ppm (t, J=7.3 Hz,
3H); 13C NMR (75 MHz, CDCl3): d=169.1, 153.5, 138.3, 137.1, 135.4,
129.2, 126.3, 123.0, 121.6, 120.0, 111.9, 82.8, 69.7, 56.6, 52.7, 52.6,
36.2, 35.2, 32.2, 25.7, 23.5, 22.0, 14.8, 11.9 ppm; HRMS (ESI) m/z :
calculated for C26H33N2O2 [M+H]
+ 405.2542, found 405.2545.
14-azido-N-((4R,4aS,7R,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-di-
hydroxy-2,3,4,4a,5,6,7,7a-octahydro-1H-4,12-methanobenzo-
furo[3,2-e]isoquinolin-7-yl)-3,6,9,12-tetraoxatetradecanamide
(11a): Compound 11a was subjected to general procedure 1. Pale-
yellow solid, 68%. 1H NMR (300 MHz, CDCl3): d=6.71 (d, J=8.1 Hz,
1H), 6.56 (dd, J=8.2 Hz, 1H), 4.45 (d, J=7.5 Hz, 1H), 4.01 (s, 2H),
3.74–3.66 (m, 14H), 3.39 (t, J=5.6 Hz, 2H), 3.10–3.04 (m, 2H), 2.99
(s, 1H), 2.67–2.54 (m, 2H), 2.40–2.34 (m, 4H), 2.24–2.13 (m, 2H),
1.89 (dd, J=12.8, 3.1 Hz, 2H), 1.70–1.40 (m, 4H), 0.90–0.77 (m, 1H),
0.57–0.48 ppm (m, 2H); 13C NMR (75 MHz, CDCl3): d=169.9, 142.4,
140.0, 131.0, 129.0, 128.2, 125.2, 119.1, 117.7, 93.5, 70.9, 70.6, 70.5,
70.5, 70.4, 70.3, 70.0, 62.3, 59.2, 50.7, 50.6, 47.7, 44.0, 30.6, 30.1,
24.4, 22.6, 9.4, 3.9, 3.7 ppm; HRMS (ESI) m/z : calculated for
C30H44N5O8 [M+H]
+ 602.3190, found 602.3205.
17-azido-N-((4R,4aS,7R,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-di-
hydroxy-2,3,4,4a,5,6,7,7a-octahydro-1H-4,12-methanobenzo-
furo[3,2-e]isoquinolin-7-yl)-3,6,9,12,15-pentaoxaheptadecana-
mide (11b): Compound 11b was subjected to general proce-
dure 1. Pale-yellow solid, 62%. 1H NMR (300 MHz, CDCl3): d=6.70
(d, J=8.1 Hz, 1H), 6.54 (d, J=8.2 Hz, 1H), 4.45 (d, J=7.5 Hz, 1H),
3.99 (s, 2H), 3.73–3.60 (m, 18H), 3.37 (t, J=5.6 Hz, 2H), 3.11 (br s,
1H), 3.01 (d, J=18.4 Hz, 1H), 2.70–2.55 (m, 2H), 2.38 (d, J=6.6 Hz,
2H), 2.26–2.10 (m, 2H), 1.87 (td, J=12.5, 2.9 Hz, 1H), 1.72–1.54 (m,
2H), 1.46 (dt, J=11.3, 2.8 Hz, 2H), 0.91–0.79 (m, 2H), 0.58–0.49 (m,
2H), 0.17–0.09 ppm (m, 2H); 13C NMR (75 MHz, CDCl3): d=170.0,
142.5, 140.1, 130.9, 124.1, 119.0, 117.8, 93.2, 70.9, 70.6, 70.6, 70.5,
70.5, 70.4, 70.30, 70.0, 70.0, 62.3, 59.1, 50.8, 50.6, 47.6, 44.1, 30.5,
30.1, 24.3, 22.6, 9.3, 3.9, 3.8 ppm; HRMS (ESI) m/z : calculated for
C32H48N5O9 [M+H]
+ 646.3452, found 646.3458.
20-azido-N-((4R,4aS,7R,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-di-
hydroxy-2,3,4,4a,5,6,7,7a-octahydro-1H-4,12-methanobenzo-
furo[3,2-e]isoquinolin-7-yl)-3,6,9,12,15,18-hexaoxaicosanamide
(11c): Compound 11c was subjected to general procedure 1. Pale-
yellow solid, 56%. 1H NMR (300 MHz, CDCl3): d=6.71 (d, J=8.1 Hz,
1H), 6.56 (d, J=8.1 Hz, 1H), 4.45 (d, J=7.5 Hz, 1H), 4.00 (s, 2H),
3.75–3.60 (m, 22H), 3.38 (t, J=5.1 Hz, 2H), 3.10–2.98 (m, 2H), 2.59
(dd, J=19.1, 6.3 Hz, 2H), 2.36 (d, J=6.5 Hz, 2H), 2.24–2.08 (m, 2H),
1.90 (qd, J=12.7, 3.2 Hz, 1H), 1.72–1.53 (m, 2H), 1.46 (dd, J=9.0,
4.4 Hz, 2H), 0.83 (dp, J=13.0, 6.3 Hz, 2H), 0.56–0.49 (m, 2H),
0.12 ppm (d, J=4.7 Hz, 2H); 13C NMR (75 MHz, CDCl3): d=169.9,
142.4, 140.0, 131.0, 124.3, 119.0, 117.7, 93.3, 70.9, 70.6, 70.6, 70.6,
70.5, 70.5, 70.4, 70.4, 70.3, 70.0, 70.0, 62.3, 59.2, 50.8, 50.6, 47.7,
44.0, 30.6, 30.1, 24.4, 22.6, 9.4, 3.9, 3.7 ppm; HRMS (ESI) m/z : calcu-
lated for C34H52N5O10 [M+H]
+ 690.3714, found 690.3744.
14-azido-N-((4R,4aR,7R,7aR,12bS)-9-hydroxy-3-methyl-
2,3,4,4a,5,6,7,7a-octahydro-1H-4,12-methanobenzofuro[3,2-e]iso-
quinolin-7-yl)-3,6,9,12-tetraoxatetradecanamide (11d): Com-
pound 11d was subjected to general procedure 1. Off-white solid,
62%. 1H NMR (300 MHz, CDCl3): d=6.66 (d, J=8.1 Hz, 1H), 6.56 (d,
J=8.1 Hz, 1H), 4.41 (d, J=7.9 Hz, 1H), 3.96 (s, 2H), 3.72–3.57 (m,
14H), 3.37 (t, J=5.6 Hz, 2H), 3.11 (br s, 1H), 2.98 (d, J=18.4 Hz,
1H), 2.54 (dd, J=11.9, 4.4 Hz, 1H), 2.39 (s, 3H), 2.34–2.14 (m, 2H),
1.92–1.75 (m, 2H), 1.71–1.48 (m, 3H), 1.42–1.23 (m, 2H), 1.14–
1.00 ppm (m, 1H); 13C NMR (75 MHz, CDCl3): d=169.9, 142.8, 140.3,
129.3, 125.2, 119.4, 117.5, 93.2, 70.8, 70.6, 70.5, 70.4, 70.4, 70.4, 70.2,
70.0, 59.4, 51.5, 50.6, 47.2, 44.9, 43.4, 42.6, 35.2, 28.8, 24.1,
20.1 ppm; HRMS (ESI) m/z : calculated for C27H40N5O7 [M+H]
+
546.2928, found 546.2923.
17-azido-N-((4R,4aR,7R,7aR,12bS)-9-hydroxy-3-methyl-
2,3,4,4a,5,6,7,7a-octahydro-1H-4,12-methanobenzofuro[3,2-e]iso-
quinolin-7-yl)-3,6,9,12,15-pentaoxaheptadecanamide (11e):
Compound 11e was subjected to general procedure 1. Off-white
solid, 53%. 1H NMR (300 MHz, CDCl3): d=6.59 (d, J=8.1 Hz, 1H),
6.51 (d, J=8.1 Hz, 1H), 4.36 (d, J=7.9 Hz, 1H), 3.92 (s, 2H), 3.73–
3.54 (m, 18H), 3.34 (t, J=5.6 Hz, 2H), 2.95 (d, J=19.1 Hz, 1H), 2.49
(dd, J=12.5, 4.2 Hz, 1H), 2.39–2.29 (m, 2H), 2.20 (s, 3H), 1.79 (dd,
J=12.4, 4.6 Hz, 2H), 1.68–1.55 (m, 2H), 1.33–1.20 (m, 2H),
1.07 ppm (t, J=7.2 Hz, 1H); 13C NMR (75 MHz, CDCl3): d=169.8,
143.0, 140.7, 129.3, 124.8, 119.2, 117.5, 92.8, 70.8, 70.6, 70.5, 70.4,
70.4, 70.3, 70.3, 70.2, 69.9, 59.3, 51.6, 47, 45.0, 43.4, 42.7 (d, J=
5.2 Hz), 38.9, 35.3, 28.9, 24.1, 20.0, 15.49 ppm; HRMS (ESI) m/z : cal-
culated for C29H44N5O8 [M+H]
+ 590.3190, found 590.3192.
20-azido-N-((4R,4aR,7R,7aR,12bS)-9-hydroxy-3-methyl-
2,3,4,4a,5,6,7,7a-octahydro-1H-4,12-methanobenzofuro[3,2-e]iso-
quinolin-7-yl)-3,6,9,12,15,18-hexaoxaicosanamide (11 f): Com-
pound 11 f was subjected to general procedure 1. Off-white solid,
51%. 1H NMR (300 MHz, CDCl3): d=6.64 (d, J=8.1 Hz, 1H), 6.54 (d,
J=8.1 Hz, 1H), 4.42 (d, J=8.0 Hz, 1H), 3.95 (s, 2H), 3.76–3.49 (m,
22H), 3.36 (t, J=5.6 Hz, 2H), 3.10 (br s, 1H), 2.93 (s, 2H), 2.86 (d, J=
0.6 Hz, 1H), 2.58–2.46 (m, 1H), 2.37 (s, 3H), 2.26–2.10 (m, 2H), 1.85
(dt, J=12.0, 6.0 Hz, 1H), 1.70–1.59 (m, 1H), 1.51 (dd, J=13.4,
3.5 Hz, 1H), 1.45–1.20 (m, 2H), 1.06 ppm (ddd, J=15.3, 10.5, 2.4 Hz,
1H); 13C NMR (75 MHz, CDCl3): d=169.9, 142.8, 140.3, 129.4, 125.2,
119.3, 117.4, 93.1, 70.8, 70.6, 70.6, 70.5, 70.5, 70.4, 70.4, 70.4, 70.3,
70.2, 69.9, 59.3, 51.7, 50.6, 47.2, 43.4, 42.7, 35.2, 28.7, 24.1,
20.0 ppm; HRMS (ESI) m/z : calculated for C31H48N5O9 [M+H]
+
634.3452, found 634.3444.
N-((4R,4aS,7R,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-dihydroxy-
2,3,4,4a,5,6,7,7a-octahydro-1H-4,12-methanobenzofuro[3,2-e]iso-
quinolin-7-yl)-14-(4-((2-methoxy-4-((4-(2-methoxyphenyl)pipera-
zin-1-yl)methyl)phenoxy)methyl)-1H-1,2,3-triazol-1-yl)-3,6,9,12-
tetraoxatetradecanamide (12a): Compound 12a was subjected to
general procedure 2. Off-white solid, 55%. LC–HRMS: tR=5.43 min
(10–100% MeCN, 15 min run), 96.49%. 1H NMR (300 MHz, CDCl3):
d=7.85 (s, 1H), 7.20 (d, J=8.7 Hz, 1H), 7.00–6.79 (m, 6H), 6.68 (d,
J=8.1 Hz, 1H), 6.53 (d, J=8.1 Hz, 1H), 5.28 (d, J=7.1 Hz, 2H), 4.53
(t, J=5.6 Hz, 2H), 4.42 (d, J=7.5 Hz, 1H), 3.93 (s, 2H), 3.87 (t, J=
5.2 Hz, 2H), 3.84 (s, 3H), 3.82 (s, 3H), 3.68–3.56 (m, 14H), 3.53 (s,
2H), 3.09–3.03 (m, 5H), 2.95 (d, J=6.4 Hz, 1H), 2.72–2.53 (m, 6H),
2.35 (d, J=6.5 Hz, 2H), 2.21–2.11 (m, 2H), 1.86 (qd, J=12.6, 3.3 Hz,
1H), 1.74–1.62 (m, 1H), 1.61–1.37 (m, 3H), 0.90–0.75 (m, 1H), 0.55–
0.47 (m, 2H), 0.15–0.07 ppm (m, 2H); 13C NMR (75 MHz, CDCl3): d=
169.8, 152.2, 149.4, 146.8, 144.1, 142.5, 141.2, 140.2, 131.1, 130.9,
124.2, 124.08, 122.8, 121.7, 120.9, 119.0, 118.2, 118.0, 113.7, 112.9,
111.1, 92.8, 70.8, 70.5, 70.4, 70.4, 70.3, 70.3, 70.0, 69.4, 63.1, 62.7,
62.3, 59.1, 55.8, 55.3, 53.1, 51.0, 50.3, 50.2, 47.6, 44.0, 30.7, 30.0,
24.4, 22.6, 9.4, 3.9, 3.7 ppm; HRMS (ESI) m/z : calculated for
C52H71N7O11 [M+2H]
2+ 484.7600, found 484.7572.
N-((4R,4aS,7R,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-dihydroxy-
2,3,4,4a,5,6,7,7a-octahydro-1H-4,12-methanobenzofuro[3,2-e]iso-
quinolin-7-yl)-17-(4-((2-methoxy-4-((4-(2-methoxyphenyl)pipera-
zin-1-yl)methyl)phenoxy)methyl)-1H-1,2,3-triazol-1-yl)-
3,6,9,12,15-pentaoxaheptadecanamide (12b): Compound 12b
was subjected to general procedure 2. Off-white solid, 52%. LC–
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HRMS: tR=5.44 min (10–100% MeCN, 15 min run), 92.62%; HRMS
(ESI) m/z : calculated for C54H75N7O12 [M+2H]
2+ 506.7731, found
506.7713.
N-((4R,4aS,7R,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-dihydroxy-
2,3,4,4a,5,6,7,7a-octahydro-1H-4,12-methanobenzofuro[3,2-e]iso-
quinolin-7-yl)-20-(4-((2-methoxy-4-((4-(2-methoxyphenyl)pipera-
zin-1-yl)methyl)phenoxy)methyl)-1H-1,2,3-triazol-1-yl)-
3,6,9,12,15,18-hexaoxaicosanamide (12c): Compound 12c was
subjected to general procedure 2. Off-white solid, 50%. LC–HRMS:
tR=5.63 min (10–100% MeCN, 15 min run), 95.23%; HRMS (ESI) m/
z : calculated for C56H79N7O13 [M+2H]
2+ 528.7862, found 528.7854.
N-((4R,4aR,7R,7aR,12bS)-9-hydroxy-3-methyl-2,3,4,4a,5,6,7,7a-oc-
tahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl)-14-
(4-((2-methoxy-4-((4-(2-methoxyphenyl)piperazin-1-yl)methyl)-
phenoxy)methyl)-1H-1,2,3-triazol-1-yl)-3,6,9,12-tetraoxatetrade-
canamide (12d): Compound 12d was subjected to general proce-
dure 2. Off-white solid, 42%. LC–HRMS: tR=5.23 min (10–100%
MeCN, 15 min run), 96.94%. 1H NMR (300 MHz, CDCl3): d=7.85 (s,
1H), 7.11 (d, J=8.2 Hz, 1H), 7.01–6.94 (m, 2H), 6.94–6.88 (m, 2H),
6.83 (ddd, J=8.1, 5.5, 1.7 Hz, 2H), 6.68 (d, J=8.1 Hz, 1H), 6.56 (d,
J=8.1 Hz, 1H), 5.28 (d, J=6.7 Hz, 2H), 4.53 (t, J=5.7 Hz, 2H), 4.42
(d, J=8.0 Hz, 1H), 3.91 (d, J=1.4 Hz, 2H), 3.87 (t, J=5.5 Hz, 2H),
3.84 (s, 3H), 3.82 (s, 3H), 3.66–3.51 (m, 14H), 3.09 (br s, 4H), 2.98–
2.85 (m, 1H), 2.66 (br s, 3H), 2.52 (dd, J=12.1, 4.6 Hz, 1H), 2.39 (s,
3H), 2.19 (dt, J=9.8, 5.3 Hz, 2H), 1.82 (td, J=12.2, 5.1 Hz, 1H), 1.58
(ddd, J=33.7, 12.6, 3.5 Hz, 2H), 1.45–1.21 (m, 1H), 1.17–0.98 ppm
(m, 1H); 13C NMR (75 MHz, CDCl3): d=169.8, 152.2, 149.4, 146.7,
144.1, 142.7, 141.2, 140.1, 131.2, 129.3, 125.3, 124.25, 122.8, 121.7,
120.9, 119.5, 118.2, 117.7, 113.7, 112.9, 111.1, 93.0, 70.8, 70.5, 70.4,
70.3, 70.3, 70.2, 69.4, 63.1, 62.8, 59.4, 55.8, 55.3, 53.2, 51.3, 50.3,
50.2, 47.2, 43.4, 42.8, 42.7, 35.3, 28.7, 24.1, 20.0 ppm; HRMS (ESI) m/
z : calculated for C49H67N7O10 [M+2H]
2+ 456.7469, found 456.7434.
N-((4R,4aR,7R,7aR,12bS)-9-hydroxy-3-methyl-2,3,4,4a,5,6,7,7a-oc-
tahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl)-17-
(4-((2-methoxy-4-((4-(2-methoxyphenyl)piperazin-1-yl)methyl)-
phenoxy)methyl)-1H-1,2,3-triazol-1-yl)-3,6,9,12,15-pentaoxahep-
tadecanamide (12e): Compound 12e was subjected to general
procedure 2. Off-white solid, 46%. LC–HRMS: tR=5.30 min (10–
100% MeCN, 15 min run), 88.20%; HRMS (ESI) m/z : calculated for
C51H71N7O11 [M+2H]
2+ 478.7600, found 478.7562.
N-((4R,4aR,7R,7aR,12bS)-9-hydroxy-3-methyl-2,3,4,4a,5,6,7,7a-oc-
tahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl)-20-
(4-((2-methoxy-4-((4-(2-methoxyphenyl)piperazin-1-yl)methyl)-
phenoxy)methyl)-1H-1,2,3-triazol-1-yl)-3,6,9,12,15,18-hexaoxai-
cosanamide (12 f): Compound 12 f was subjected to general pro-
cedure 2. Off-white solid, 40%. LC–HRMS: tR=5.37 min (10–100%
MeCN, 15 min run), 92.86%. 1H NMR (300 MHz, CDCl3): d=7.84 (s,
1H), 7.22 (d, J=9.7 Hz, 1H), 7.02–6.88 (m, 4H), 6.82 (t, J=8.0 Hz,
2H), 6.66 (d, J=8.0 Hz, 1H), 6.55 (d, J=8.1 Hz, 1H), 5.26 (s, 2H),
4.71 (s, 0H), 4.52 (t, J=5.1 Hz, 2H), 4.43 (dd, J=8.0, 3.6 Hz, 1H),
3.92 (s, 2H), 3.85 (d, J=4.3 Hz, 5H), 3.81 (d, J=3.0 Hz, 3H), 3.77–
3.45 (m, 29H), 3.19–2.98 (m, 6H), 2.98–2.92 (m, 1H), 2.65 (t, J=
4.8 Hz, 4H), 2.51 (dd, J=11.9, 4.4 Hz, 1H), 2.38 (s, 3H), 2.18 (dt, J=
15.9, 5.0 Hz, 2H), 1.82 (dt, J=11.6, 5.3 Hz, 2H), 1.71–1.47 (m, 2H),
1.44–1.23 (m, 1H), 1.15–0.99 ppm (m, 1H); 13C NMR (75 MHz,
CDCl3): d=169.9, 152.2, 149.4, 146.8, 144.1, 142.7, 141.3, 140.2,
131.3 (d, J=4.5 Hz), 129.3, 125.3, 124.2, 122.8, 121.6, 120.9, 119.4,
118.2, 117.5, 113.7, 112.8, 111.1, 93.1, 70.8, 70.5, 70.4, 70.3, 70.2,
69.4, 63.1, 62.8, 59.4, 55.8, 55.3, 53.2, 51.8, 50.3 (d, J=14.4 Hz), 47.2,
43.4, 42.8 (d, J=8.3 Hz), 35.3, 28.7, 24.2, 20.1 ppm; HRMS (ESI) m/z :
calculated for C53H75N7O12 [M+2H]
2+ 500.7731, found 500.7742.
N-((4R,4aS,7R,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-dihydroxy-
2,3,4,4a,5,6,7,7a-octahydro-1H-4,12-methanobenzofuro[3,2-e]iso-
quinolin-7-yl)-14-(4-(3-((4-(2-((5-hydroxy-1,2,3,4-tetrahydronaph-
thalen-2-yl)(propyl)amino)ethyl)phenyl)amino)-3-oxopropyl)-1H-
1,2,3-triazol-1-yl)-3,6,9,12-tetraoxatetradecanamide (13a): Com-
pound 13a was subjected to general procedure 2. Off-white solid,
60%. LC–HRMS: tR=5.43 min (10–100% MeCN, 15 min run),
99.45%. 1H NMR (300 MHz, CDCl3): d=7.40 (d, J=8.2 Hz, 2H), 7.22
(d, J=8.9 Hz, 1H), 7.08 (d, J=8.4 Hz, 2H), 6.94 (t, J=7.8 Hz, 1H),
6.72 (d, J=8.1 Hz, 1H), 6.62 (d, J=7.9 Hz, 2H), 6.53 (d, J=8.2 Hz,
1H), 4.47 (t, J=5.1 Hz, 2H), 4.41 (d, J=7.5 Hz, 1H), 3.92 (s, 2H),
3.83 (t, J=5.2 Hz, 2H), 3.64–3.56 (m, 14H), 3.07 (dt, J=15.4, 6.3 Hz,
3H), 2.99–2.85 (m, 2H), 2.76 (dt, J=14.2, 7.4 Hz, 6H), 2.56 (dt, J=
17.0, 7.8 Hz, 4H), 2.35 (d, J=6.5 Hz, 2H), 2.20–1.99 (m, 3H), 1.85 (q,
J=12.8 Hz, 1H), 1.71–1.36 (m, 6H), 1.25 (s, 1H), 0.89 (t, J=7.3 Hz,
3H), 0.56–0.48 (m, 2H), 0.11 ppm (q, J=5.0 Hz, 2H); 13C NMR
(75 MHz, CDCl3): d=170.6, 170.1, 153.8, 146.2, 142.5, 140.3, 137.9,
136.2 (d, J=9.1 Hz), 130.3, 129.1, 126.3, 124.0, 123.1, 122.9, 121.3,
119.9, 119.1, 118.0, 112.1, 92.6, 77.2, 74.6, 70.8, 70.5, 70.4, 70.4, 70.3,
70.3, 70.1, 69.4, 62.3, 59.1, 56.8, 53.4, 52.7 (d, J=18.9 Hz), 51.0, 50.2,
47.6, 44.1, 36.5, 34.9, 32.0, 30.6, 30.0, 25.6, 24.5, 23.5, 22.6, 21.7,
21.3, 11.9, 9.4, 3.9, 3.7 ppm; HRMS (ESI) m/z : calculated for
C56H77N7O10 [M+2H]
2+ 503.7860, found 503.7833.
N-((4R,4aS,7R,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-dihydroxy-
2,3,4,4a,5,6,7,7a-octahydro-1H-4,12-methanobenzofuro[3,2-e]iso-
quinolin-7-yl)-17-(4-(3-((4-(2-((5-hydroxy-1,2,3,4-tetrahydronaph-
thalen-2-yl)(propyl)amino)ethyl)phenyl)amino)-3-oxopropyl)-1H-
1,2,3-triazol-1-yl)-3,6,9,12,15-pentaoxaheptadecanamide (13b):
Compound 13b was subjected to general procedure 2. Off-white
solid, 47%. LC–HRMS: tR=5.48 min (10–100% MeCN, 15 min run),
95.65%. 1H NMR (300 MHz, CDCl3): d=7.59 (s, 1H), 7.40 (d, J=
8.4 Hz, 2H), 7.08 (d, J=8.3 Hz, 2H), 6.95 (t, J=7.8 Hz, 1H), 6.72 (d,
J=8.1 Hz, 1H), 6.62 (t, J=7.8 Hz, 2H), 6.54 (d, J=8.1 Hz, 1H), 3.92
(s, 2H), 3.81 (t, J=5.0 Hz, 2H), 3.72–3.48 (m, 18H), 3.17–3.02 (m,
3H), 3.02–2.85 (m, 2H), 2.85–2.65 (m, 5H), 2.63–2.49 (m, 4H), 2.35
(d, J=6.5 Hz, 2H), 2.15 (s, 1H), 1.61–1.38 (m, 3H), 0.89 (t, J=7.3 Hz,
3H), 0.55–0.47 (m, 2H), 0.14–0.09 ppm (m, 2H); 13C NMR (75 MHz,
CDCl3): d=170.6, 170.0, 153.6, 146.2, 142.5, 140.2, 138.2, 136.5,
136.1, 130.9, 129.0, 126.2, 124.1, 123.1, 122.8, 121.4, 119.8, 119.0,
118.0, 112.0, 92.7, 77.2, 70.8, 70.5, 70.5, 70.4, 70.3, 70.3, 70.1, 69.4,
62.3, 59.1, 56.6, 52.8, 52.5, 51.0, 50.2, 47.7, 44.0, 36.5, 35.2, 32.1,
30.6, 30.0, 25.7, 24.4, 23.5, 22.6, 21.9, 21.3, 11.9, 9.4, 3.9, 3.7 ppm;
HRMS (ESI) m/z : calculated for C58H81N7O11 [M+2H]
2+ 525.7991,
found 525.8002.
N-((4R,4aS,7R,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-dihydroxy-
2,3,4,4a,5,6,7,7a-octahydro-1H-4,12-methanobenzofuro[3,2-e]iso-
quinolin-7-yl)-20-(4-(3-((4-(2-((5-hydroxy-1,2,3,4-tetrahydronaph-
thalen-2-yl)(propyl)amino)ethyl)phenyl)amino)-3-oxopropyl)-1H-
1,2,3-triazol-1-yl)-3,6,9,12,15,18-hexaoxaicosanamide (13c):
Compound 13c was subjected to general procedure 2. Off-white
solid, 43%. LC–HRMS: tR=5.53 min (10–100% MeCN, 15 min run),
98.35%; HRMS (ESI) m/z : calculated for C60H85N7O12 [M+2H]
2+
547.8122, found 547.8098.
14-(4-(3-((4-(2-((5-hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)-
(propyl)amino)ethyl)phenyl)amino)-3-oxopropyl)-1H-1,2,3-tri-
azol-1-yl)-N-((4R,4aR,7R,7aR,12bS)-9-hydroxy-3-methyl-
2,3,4,4a,5,6,7,7a-octahydro-1H-4,12-methanobenzofuro[3,2-e]iso-
quinolin-7-yl)-3,6,9,12-tetraoxatetradecanamide (13d): Com-
pound 13d was subjected to general procedure 2. Off-white solid,
52%. LC–HRMS: tR=5.26 min (10–100% MeCN, 15 min run),
98.63%. 1H NMR (300 MHz, CDCl3): d=8.23 (s, 1H), 7.59 (s, 1H),
7.39 (d, J=8.3 Hz, 2H), 7.09 (d, J=8.1 Hz, 2H), 6.96 (t, J=7.7 Hz,
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1H), 6.72 (d, J=8.1 Hz, 1H), 6.64 (d, J=7.6 Hz, 1H), 6.58 (dd, J=
8.0, 4.2 Hz, 2H), 4.47 (t, J=5.0 Hz, 2H), 4.37 (d, J=7.9 Hz, 1H), 3.92
(s, 2H), 3.82 (t, J=5.0 Hz, 2H), 3.69–3.50 (m, 14H), 3.11 (d, J=
6.9 Hz, 3H), 2.98–2.85 (m, 3H), 2.83–2.66 (m, 6H), 2.55 (dd, J=8.6,
6.5 Hz, 3H), 2.41 (s, 3H), 2.19 (d, J=12.6 Hz, 2H), 2.02 (d, J=
12.6 Hz, 1H), 1.81 (td, J=12.2, 11.3, 7.1 Hz, 2H), 1.69–1.57 (m, 1H),
1.50 (q, J=7.1 Hz, 3H), 1.25 (s, 3H), 0.89 ppm (t, J=7.3 Hz, 3H);
13C NMR (75 MHz, CDCl3): d=170.6, 169.9, 146.2, 153.8, 142.8,
140.2, 136.6, 136.0, 129.1, 126.3, 123.2, 122.8, 121.3, 119.8, 119.5,
117.8, 112.0, 93.0, 70.7, 70.5, 70.4, 70.4, 70.2, 70.2, 69.4, 59.5, 56.7,
53.4, 51.6, 50.1, 47.2, 43.3, 42.5, 36.6, 35.2, 32.1, 29.6, 28.7, 25.7,
24.0, 23.5, 21.9, 21.4, 20.1, 11.9 ppm; HRMS (ESI) m/z : calculated for
C53H73N7O9 [M+2H]
2+ 475.7729, found 475.7702.
17-(4-(3-((4-(2-((5-hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)-
(propyl)amino)ethyl)phenyl)amino)-3-oxopropyl)-1H-1,2,3-tri-
azol-1-yl)-N-((4R,4aR,7R,7aR,12bS)-9-hydroxy-3-methyl-
2,3,4,4a,5,6,7,7a-octahydro-1H-4,12-methanobenzofuro[3,2-e]iso-
quinolin-7-yl)-3,6,9,12,15-pentaoxaheptadecanamide (13e):
Compound 13e was subjected to general procedure 2. Off-white
solid, 48%. LC–HRMS: tR=5.33 min (10–100% MeCN, 15 min run),
95.43%; HRMS (ESI) m/z : calculated for C55H77N7O10 [M+2H]
2+
497.7860, found 497.7826.
20-(4-(3-((4-(2-((5-hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)-
(propyl)amino)ethyl)phenyl)amino)-3-oxopropyl)-1H-1,2,3-tri-
azol-1-yl)-N-((4R,4aR,7R,7aR,12bS)-9-hydroxy-3-methyl-
2,3,4,4a,5,6,7,7a-octahydro-1H-4,12-methanobenzofuro[3,2-e]iso-
quinolin-7-yl)-3,6,9,12,15,18-hexaoxaicosanamide (13 f): Com-
pound 13 f was subjected to general procedure 2. Off-white solid,
44%. LC–HRMS: tR=5.37 min (10–100% MeCN, 15 min run),
97.02%. 1H NMR (300 MHz, CDCl3): d=8.48 (d, J=7.4 Hz, 1H), 7.59
(s, 1H), 7.40 (d, J=7.9 Hz, 2H), 7.07 (d, J=8.0 Hz, 2H), 6.93 (t, J=
7.7 Hz, 1H), 6.69 (d, J=8.1 Hz, 1H), 6.58 (q, J=8.6 Hz, 3H), 5.29 (s,
1H), 4.52–4.35 (m, 3H), 3.90 (s, 2H), 3.79 (t, J=5.0 Hz, 2H), 3.71–
3.42 (m, 22H), 3.10 (t, J=6.7 Hz, 3H), 2.94 (td, J=13.9, 13.5, 7.0 Hz,
2H), 2.83–2.62 (m, 6H), 2.62–2.44 (m, 4H), 2.38 (s, 3H), 2.18 (dt, J=
12.5, 4.2 Hz, 2H), 2.02 (d, J=11.2 Hz, 1H), 1.80 (t, J=11.9 Hz, 1H),
1.69–1.40 (m, 4H), 1.27 (d, J=12.9 Hz, 1H), 1.03 (t, J=12.9 Hz, 1H),
0.88 ppm (t, J=7.3 Hz, 3H); 13C NMR (75 MHz, CDCl3): d=170.6,
170.1, 154.1, 146.3, 142.8, 140.3, 138.1, 136.4, 136.2, 129.2, 129.0,
126.2, 125.0, 123.4, 122.9, 121.0, 119.8, 119.4, 117.7, 111.9, 92.9,
70.7, 70.5, 70.4, 70.3, 70.3, 70.2, 69.3, 59.4, 56.7, 52.8, 52.6, 51.6,
50.2, 47.2, 43.3, 42.5 (d, J=11.1 Hz), 36.4, 35.1 (d, J=8.9 Hz), 32.2,
28.7, 25.8, 24.1, 23.7, 22.0, 21.3, 20.1 ppm; HRMS (ESI) m/z : calculat-
ed for C57H81N7O11 [M+2H]
2+ 519.7991, found 519.7953.
Plasmids and receptor fusion constructs
The plasmids HA D4.2 and HA D2 were described previously.
[39] The
NanoBiT constructs (NB MCS1) and (NB MCS2) were procured from
Promega. These plasmids encode for the split fragments of Nano-
luciferase: LargeBiT (LgBiT) and SmallBiT (SmBiT). The human mOR
was PCR amplified and SmBiT was cloned at the C-terminus of the
receptor. A flexible linker (GSSGGGGSGGGGSSG) is present in be-
tween mOR and SmBiT. To clone mOR-SmBiT, specific primers were
generated with a HindIII restriction site at the 5’ terminus and a
XhoI site at the 3’ terminus of the mOR coding sequence by remov-
ing the stop codon. PCR was performed with 20 ng of plasmid
with Pfu DNA Polymerase (2.5 UmL@1, Thermo Fisher Scientific) ac-
cording to the manufacturer’s protocol. The reactions were per-
formed in a Mastercycler Nexus Thermal Cycler (Eppendorf, Ham-
burg, Germany) and then purified using QIAquick Gel Extraction Kit
(QIAGEN, Germany). The resultant amplicon and the vector (NB
MCS2) were digested with HindIII and XhoI for 3 h at 37 8C. The di-
gested PCR product was cleaned using “High Pure PCR Product Pu-
rification Kit” (Roche, Germany) and then ligated into the corre-
sponding digested NB MCS2. After transformation of the ligated
product into competent MC 1061 “E. coli” strain, the ampicillin re-
sistant clones were screened by performing PCR with primers
against mOR. Furthermore, a digestion was performed with HindIII
and XbaI, which are the restriction sites flanking mOR-SmBiT. The
constructs were verified by sequencing. LgBiT-b-arrestin 2 has been
previously described.[32]
Cell culture and transfection
Human embryonic kidney (HEK) 293T cells were cultured in Dulbec-
co’s modified Eagle’s medium (DMEM; Invitrogen), supplemented
with 10% fetal bovine serum, penicillin (100 UmL@1), and strepto-
mycin (100 mgmL@1) in a controlled environment (37 8C, 98% hu-
midity, 5% CO2). For ligand binding experiments and b-arrestin 2
recruitment assay, HEK293T cells were transiently transfected using
the Polyethylenimine (PEI) method as described before.[30] A total
amount of 10 mg of DNA was used for transfection of cells in one
10 cm dish. HEK293S cells stably expressing HA D4.2R
30 were grown
in DMEM/F12 (Gibco, Invitrogen) supplemented with 10% fetal
bovine serum, penicillin (100 UmL@1), streptomycin (100 mgmL@1),
and 0.5 mgmL@1 G418 (Geneticin, Gibco) in a controlled environ-
ment (37 8C, 98% humidity, 5% CO2).
Membrane preparation and protein determination
Membrane suspensions from HEK293T cells transiently transfected
with the receptors of interest were prepared as described previous-
ly.[27, 28] Cells were disrupted with a Polytron homogenizer for two
10 s periods in 10 volumes of ice-cold Tris·HCl buffer (50 mm,
pH 7.4). Membranes were obtained by centrifugation at 16500 g
for 20 min at 4 8C, and the pellet was resuspended and centrifuged
under the same conditions. The resulting pellet was stored at
@80 8C and was washed once more as described above and resus-
pended in Tris·HCl buffer (50 mm, pH 7.4) for immediate use. Pro-
tein was quantified by the BCA method using bovine serum albu-
min dilutions as the standard.
[3H]Spiperone binding
Saturation binding assay for [3H]spiperone was performed as previ-
ously.[27,28] For competition binding assays, membranes (20 mg)
were incubated in binding buffer (50 mm Tris·HCl containing 5 mm
KCl, 1 mm EDTA, 1.5 mm CaCl2 and 4 mm MgCl2, pH 7.4) with
0.2 nm [3H] spiperone (specific activity=76 Cimmol@1, PerkinElmer,
USA) in the absence or presence of 11 different concentrations
(0.1 nm–10 mm) of unlabeled ligands for 1 h at 22 8C. Nonspecific
binding was determined in the presence of 1 mm haloperidol. Incu-
bation was terminated by rapid filtration through GF/C glass-fiber
filters (Whatman Schleicher and Schuell, Keene, NH) embedded in
0.1% polyethylenimine and mounted on a Brandel cell harvester.
Filters were washed three times with cold 50 mm Tris·HCl, pH 7.4
buffer and transferred to vials containing 3 mL of scintillation cock-
tail to soak the filter overnight. The radioactivity counts were mea-
sured with a Tri-Carb 2800TR liquid scintillation analyzer (Perki-
nElmer).
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[3H]Raclopride binding
[3H]raclopride saturation binding assay was performed as described
before.[40] Briefly, a suspension of whole cells (corresponding a total
protein amount of 20 mg) were incubated with different concentra-
tions (0–20 nm) of [3H]raclopride in 50 mm Tris·HCl, pH 7.4 buffer
(containing 5 mm KCl, 100 mm NaCl, 1.5 mm CaCl2, 4 mm MgCl2
and 1 mm EDTA) at 37 8C for 1 h. For competitive binding experi-
ments, 2.0 nm [3H]raclopride (specific activity=73.8 Cimmol@1, Per-
kinElmer, USA) was incubated with 20 mg of whole cells in the ab-
sence or presence of varying concentrations (0.1 nm@10 mm) of un-
labeled ligands at 37 8C for 1 h. Nonspecific binding was deter-
mined in the presence of 1 mm haloperidol. Free and cell-bound
ligand were separated by rapid filtration through GF/C glass-fiber
filters (Whatman Schleicher and Schuell, Keene, NH) embedded in
0.1% polyethylenimine and mounted on a Brandel cell harvester.
Filtration and measuring were as described above.
[3H]Diprenorphine binding
[3H]diprenorphine saturation binding assay was adapted from a
published protocol.[41] Membranes (10 mg) were incubated with dif-
ferent concentrations (0–6 nm) of [3H]diprenorphine in 50 mm
Tris·HCl, pH 7.4 buffer at 25 8C for 1 h. For competitive binding ex-
periments, 0.5 nm [3H]diprenorphine (specific activity=
25.8 Cimmol@1, PerkinElmer, USA) was incubated with 10 mg of
membranes in the absence or presence of varying concentrations
(0.1 nm@10 mm) of unlabeled ligands at 25 8C for 1 h. Nonspecific
binding was determined in the presence of 10 mm naloxone. Filtra-
tion and measuring were as described above.
Data analysis : Results are expressed as means : SEM for at least
three experiments, each performed in duplicate. Statistical analysis
and curve fits of dose-response curves were performed using
GraphPad Prism 7. Ki values were calculated by using the Cheng–
Prusoff equation.[42]
MAPK phosphorylation
HEK293S cells stably expressing HA D4.2R were seeded in 6-well
plates at 400000 cells per well. When the cells were 70% conflu-
ent, cells were starved overnight with serum free medium. The li-
gands (1 nm–10 mm) were added sequentially to the cells at the
concentrations indicated in the legend for 5 min. To stop the reac-
tion, medium was aspirated, the cells were placed on ice and
washed with ice-cold PBS. RIPA buffer [150 mm NaCl; 50 mm Tris/
HCl pH 7.5; 1% NP-40; 0.1% SDS; and 0.5% deoxycholic acid
sodium salt (Acros Organics: 218591000). protease inhibitors : apro-
tinin (2.5 mgmL@1, Sigma–Aldrich: A6279), pefablock (1 mm, Sigma–
Aldrich: 76307), leupeptin (10 mgmL@1, Acros Organics:
328350050), and phosphatase inhibitor b-glycerol phosphate diso-
dium salt pentahydrate (10 mm, Fluka BioChemika: 50020) was
used to prepare the cell lysate for western blotting according to
the protocol described before.[43] After western blotting, the mem-
brane was incubated with blocking buffer (LI-COR Biosciences) for
1 h at RT. Then, primary antibody rabbit polyclonal phospho-p44/
42 MAPK (1/2000) (Cell Signaling, cat. no. 9101L) or mouse mono-
clonal p44/42 MAPK (1/2000) (clone L34F12; Cell Signaling, cat. no.
4696S) was added to develop the blot overnight at 4 8C. Next, the
blot was washed with washing buffer (PBS + 0.05% Tween 20
from Sigma–Aldrich) for three times and then secondary antibodies
goat anti-rabbit IRDye680 LT (1/10000) (cat. no. 926-68021, LI-COR
Biosciences) or goat anti-mouse IRDye800 (1/10000) (cat. no.926-
32210, LI-COR Biosciences) were added for 1 h at RT in the dark.
The blot was washed three times with washing buffer and the fluo-
rescent signal was detected with the Odyssey Infrared Imaging
system. In the analysis, the phospho-p44/42 MAPK signal is normal-
ized against the total p44/42 MAPK signal after quantification by
ImageJ.
b-Arrestin 2 recruitment
HEK293T cells were seeded in 10-cm dishes with 2.5V106 cells/dish
and transiently transfected with pmOR-SmBiT (4 mg), pLgBiT-b-ar-
restin 2 (1 mg), pGRK2 (1 mg) and pcDNA3 (4 mg) per 10-cm dish.
Forty-eight hours after transfection, the cells were washed with
warm PBS, a cell suspension was prepared with warm HBSS and
proteins were estimated by the bicinchoninic acid method (BCA,
Thermo Scientific) using bovine serum albumin dilutions as the
standard. The cell suspension was added to a 96-well plate (100 mL
cell suspension in each well corresponding to 800 ng protein). The
Nano-Glo Live Cell reagent, a nonlytic detection reagent containing
the cell permeable furimazine substrate, was prepared by diluting
the Nano-Glo Live Cell substrate 20V using Nano-Glo LCS Dilution
buffer, and 25 mL was added to each well. Subsequently, the plate
was placed in the luminodetecter (CLARIOstar) for measurement.
Luminescence was monitored during the equilibration period until
the signal was stabilized before adding the agonists of mOR
(0.1 nm@10 mm, 14 mL). After adding the test compounds, lumines-
cence was continuously detected for 20–22 cycles. Solvent controls
were run in all experiments.
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